Pharmacokinetics of enrofloxacin and danofloxacin in plasma, inflammatory exudate, and bronchial secretions of calves following subcutaneous administration

Antimicrobial Agents and Chemotherapy

Volumn 43, Issue 8, 1999, Pages 1988-1992

  McKellar, Quintin ^a,c   Gibson, Ian ^a   Monteiro, Ana ^a   Bregante, Miguel ^b  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b UNIVERSITY OF ZARAGOZA   (Spain)

^c MOREDUN RESEARCH INSTITUTE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; DANOFLOXACIN; ENROFLOXACIN;

ARTICLE; BRONCHUS SECRETION; CATTLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; EXUDATE; MALE; NONHUMAN; PHARMACOKINETICS; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0032840507     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.43.8.1988     Document Type: Article

References (24)

1. Boothe, D., E. Hawkins, A. Guinn, and D. Aucoin. 1996. Accumulation of enrofloxacin and its active metabolite ciprofloxacin in lung tissues of the dog. J. Vet. Intern. Med. 10:165.
2. Dunne, A. 1985. JANA: a new iterative polyexponential curve stripping program. Comput. Methods Programs Biomed. 20:269-275.
3. Forrest, A., D. E. Nix, C. H. Ballow, T. F. Gotss, M. C. Birmingham, and J. J. Schentag. 1993. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob. Agents Chemother. 37:1073-1081.
4. Friis, C. 1993. Penetration of danofloxacin into the respiratory tract tissues and secretion in calves. Am. J. Vet. Res. 53:1122-1127.
5. Gibaldi, M., and D. Perrier. 1982. Pharmacokinetics. Marcel Dekker, New York, N.Y.
6. Giles, C. J., R. A. Magonigle, W. T. R. Grimshaw, A. C. Tanner, J. E. Risk, M. J. Lynch, and J. R. Rice. 1991. Clinical pharmacokinetics of parenterally administered danofloxacin in cattle. J. Vet. Pharmacol. Ther. 14:400-410.
7. Gilmour, N. J. L. 1983. The experimental production of pneumonic pasteurellosis in sheep and calves, p. 269-275. In G. Keusch and T. Wadstrom (ed.), Experimental bacterial and parasitic infections. Elsevier, New York, N.Y.
8. Grimshaw, W. T. R., C. J. Giles, A. C. Cooper, and D. J. Shanks. 1990. The efficacy of danofloxacin in the therapy of pneumonia associated with Pasteurella species in housed calves. Dtsch. Tieraerztl. Wochenschr. 97:529-532.
9. Gutierrez Martin, C. B., and E. F. Rodriguez Ferri. 1993. In vitro susceptibility of Pastuerella multocida subspecies multocida strains isolated from swine to 42 antimicrobial agents. Zentbl. Bakteriol. 270:387-393.
10. Hannan, P. C. T., G. D. Windsor, A. de Jong, N. Schmeer, and M. Sregemann. 1997. Comparative susceptibilities of various animal-pathogenic mycoplasmas to fluoroquinolones. Antimicrob. Agents Chemother. 41:2037-2040.
11. Higgins, A. J., P. Lees, and J. A. Wright. 1984. A tissue cage model for the collection of inflammatory exudate in ponies. Res. Vet. Sci. 36:284-289.
12. Highland, R., D. Copeland, J. Davidson, T. TerHune, K. Lechtenberg, E. Johnson, D. Miles, M. Apley, and M. Wray. 1994. Dose determination and clinical evaluation of the efficacy of enrofloxacin injectable solution in the treatment of bovine respiratory disease, p. 627-630. In Proceedings of the 18th World Buiatrics Congress.
13. Kaartinen, L., M. Salonen, L. Alli, and S. Pyorala. 1995. Pharmacokinetics of enrofloxacin after single intravenous, intramuscular and subcutaneous injections in lactating cows. J. Vet. Pharmacol. Ther. 18:357-362.
14. Kissane, J. M. 1997. Bacterial diseases, p. 369-414. In W. A. D. Anderson and J. M. Kissane (ed.), Pathology, 7th ed. Mosby, St. Louis, Mo.
15. Küng, K., J.-L. Riond, S. Wolfram, and M. Wanner. 1993. Comparison of an HPLC and bioassay method to determine antimicrobial concentrations after intravenous and oral administration of enrofloxacin in four dogs. Res. Vet. Sci. 54:247-248.
16. McKellar, Q. A., I. F. Gibson, and R. Z. McCormack. 1998. Pharmacokinetics and tissue disposition of danofloxacin in sheep. Biopharm. Drug Dispos. 19:123-129.
17. Pirro, F., M. Scheer, and A. de Jong. 1997. Additive in vitro activity of enrofloxacin and its main metabolite ciprofloxacin, p. 199. In Proceedings of the 14th Annual Congress of the European Society of Veterinary Dermatology and the European College of Veterinary Dermatology.
18. Prescott, J. F., and J. D. Baggot. 1993. Fluoroquinolones, p. 252-262. In J. F. Prescott and J. D. Baggot (ed.), Antimicrobial therapy in veterinary medicine. Iowa State University Press, Ames.
19. Richez, P., B. Dellac, R. Froyman, and A. de Jong. 1994. Pharmacokinetics of enrofloxacin in calves and adult cattle after single and repeated subcutaneous injections, p. 232-234. In P. Lees (ed.), 6th European Association for Veterinary Pharmacology and Toxicology. Blackwell Scientific Publications, Edinburgh, United Kingdom.
20. Scheer, M., and A. de Jong. 1997. Concentrations of fluoroquinolones in intestinal tract tissues after intramuscular administration to calves, p. 50-51. In A. Anadon and Q. McKellar (ed.), 7th European Association for Veterinary Pharmacology and Toxicology. Blackwell Scientific Publications, Edinburgh, United Kingdom.
21. Sullivan, M. C., B. W. Cooper, C. H. Nightingale, R. Quintiliani, and M. T. Lawlor. 1993. Evaluation of the efficacy of ciprofloxacin against Streptococcus pneumoniae by using a mouse protection model. Antimicrob. Agents Chemother. 37:234-239.
22. Vancutsem, P. M., J. G. Babish, and W. S. Schwark. 1990. The fluoroquinolone antimicrobials: structure antimicrobial activity, pharmacokinetics, clinical use in domestic animals and toxicity. Cornell Vet. 80:173-186.
23. Walker, R. D., G. F. Stein, J. G. Hauptman, and K. H. Macdonald. 1992. Pharmacokinetic evaluation of enrofloxacin administered orally to healthy dogs. Am. J. Vet. Res. 53:2315-2319.
24. Watts, J. L., R. J. Yancey, Jr., and C. A. Case. 1992. Resistance trends in bovine respiratory disease isolates, abstr. C-352, p. 479. In Abstracts of the 92nd General Meeting of the American Society for Microbiology. American Society for Microbiology, Washington, D.C.